35.87

0.34% 0.12

After Hours: 35.87

Crinetics Pharmaceuticals Inc (CRNX)

Overview News Price History Option Chain Financials Why CRNX Down? Discussions Forecast

Crinetics Pharmaceuticals Inc stock is traded at $35.87, with a volume of 2.01M. It is up +0.34% in the last 24 hours and up +3.37% over the past month. Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Previous Close:

$35.75

Open:

$36.34

24h Volume:

2.01M

Relative Volume:

1.70

Market Cap:

$3.78B

Revenue:

$18.07M

Net Income/Loss:

$-496.39M

P/E Ratio:

-6.9877

EPS:

-5.1333

Net Cash Flow:

$-419.52M

1W Performance:

+6.98%

1M Performance:

+3.37%

6M Performance:

-20.54%

1Y Performance:

+17.61%

1-Day Range:

$35.05

$36.79

1-Week Range:

$33.40

$36.79

52-Week Range:

$25.83

$57.99

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name

Crinetics Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

858-450-6464

Address

6055 LUSK BLVD., SAN DIEGO, CA

Employee

594

Twitter

@Crinetics

Next Earnings Date

2026-08-06

Latest SEC Filings

CRNX's Discussions on Twitter

Compare CRNX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRNX Crinetics Pharmaceuticals Inc	35.87	3.77B	18.07M	-496.39M	-419.52M	-5.1333
VRTX Vertex Pharmaceuticals Inc	451.63	116.49B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	55.49B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.75B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	33.54B	742.00K	-1.37B	-1.07B	-7.0731

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Upgrade	Goldman	Neutral → Buy
Jul-10-25	Initiated	Goldman	Neutral
Mar-25-25	Initiated	Stifel	Buy
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy
Mar-06-24	Initiated	Citigroup	Buy
Jan-16-24	Initiated	Morgan Stanley	Overweight
Dec-21-23	Initiated	Jefferies	Hold
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-31-23	Initiated	Oppenheimer	Outperform
Apr-24-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Robert W. Baird	Outperform
Nov-30-21	Initiated	JMP Securities	Mkt Outperform
Nov-23-21	Initiated	Evercore ISI	Outperform
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-23-19	Initiated	ROTH Capital	Buy
Feb-14-19	Initiated	H.C. Wainwright	Buy
Aug-13-18	Initiated	JP Morgan	Neutral
Aug-13-18	Initiated	Leerink Partners	Outperform
Aug-13-18	Initiated	Piper Jaffray	Overweight

View All

Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News

Jun 18, 2026

Crinetics (CRNX) director sells 6,900 shares under 10b5-1 trading plan - Stock Titan

Jun 18, 2026